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unicampAbstract Purpose: The miRNA-regulating enzymes Dicer and Drosha exhibit aberrant
expression in several cancer types. Dicer and Drosha play a crucial role during the angioge-
netic process in vitro and, for Dicer, in vivo. We aimed to investigate the potential role of
Dicer and Drosha in predicting response to Bevacizumab-based therapy in advanced colorec-
tal cancer (CRC) patients.
Methods: Dicer and Drosha mRNA levels were analysed in formalin-ﬁxed parafﬁn-embedded
specimens from patients affected by advanced CRC treated with or without Bevacizumab-
containing regimens (n = 116 and n = 50, respectively) and from patients with diverticulosis
as control group (n = 20). The experimental data were obtained using qRT-PCR, analysed
comparing Dicer and Drosha expression levels in tumour samples versus normal mucosa
and then compared to clinical outcome.
Results: The tumour samples from Bevacizumab-treated patients showed a signiﬁcantly
higher Drosha expression (P < .001) versus normal mucosa, while Dicer levels did not differ.
Intriguingly, we found that low Dicer levels predicted a longer progression-free survival (PFS)lsevier Ltd. All rights reserved.
14
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us.it (B. Vincenzi).
1502 B. Vincenzi et al. / European Journal of Cancer 49 (2013) 1501–1508(P < .0001) and overall survival (OS) (P = .009). In addition, low Dicer levels were associated
with better response to Bevacizumab-based treatments versus high Dicer levels (1.7% complete
responses and 53.4% partial responses versus 0% and 32.7%, respectively; P = .0067). Multi-
variate analysis identiﬁed three independent predictors of improved OS: high performance sta-
tus (PS) (relative risk (RR) 1.45; P = .011), lower organs involvement (RR 0.79; P = .034) and
low Dicer expression (RR 0.71; P = .008). Conversely, Drosha levels were not associated with
prognosis and outcome associated with treatment. In non-Bevacizumab-treated patients,
Dicer and Drosha expression did not correlate with outcome.
Conclusion: These ﬁndings suggest that low Dicer mRNA levels seem to be independent pre-
dictors of favourable outcome and response in patients affected by advanced CRCs treated
with Bevacizumab-based therapy.
 2012 Elsevier Ltd. All rights reserved.1. IntroductionColorectal cancer (CRC) is the third world’s leading
cause of cancer death. About 40–50% of newly diag-
nosed patients account for a metastatic disease, which
is associated with high mortality.1 The pathogenesis of
CRC is a complex process, tightly controlled by multiple
regulatory mechanisms including genome structure rear-
rangements, chromatin remodelling, epigenetic altera-
tions and genetic mutations.2 In the past few years, a
gradually increasing number of studies documented that
these processes are regulated by a class of small noncod-
ing RNAs called microRNAs (miRNA) and involved in
a wide spectrum of biological processes.3
Recent evidences have shown that alteration in miR-
NA expression is involved in the pathogenesis of cancers
and in the metastatization process. The master regula-
tors of miRNA biogenesis are two ribonucleases called
Dicer and Drosha that act at diﬀerent stages of miRNA
synthesis and maturation. In the “miRNA machinery”,
Drosha is involved in the initial step of miRNA process-
ing in the nucleus, where short (60–70 nucleotides) dou-
ble-stranded RNA precursors (pre-miRNAs) are
generated.4
Subsequently, the resulting pre-miRNA is exported
to the cytoplasm and then cleaved by Dicer to generate
the mature products, double-stranded miRNA frag-
ments of 15–30 nucleotides.5–7
Some studies suggest that these factors, required for
the biogenesis of miRNAs, are also implicated in cancer
development. Growing evidences indeed show that
Dicer and Drosha expression levels may vary among
tumour types, but the regulation of these genes is still
unclear. Recently, Karube et al. indicated that levels of
Dicer could be used as prognostic markers in non-small
cell lung cancer (NSCLC) and in breast cancer patients,
showing that reduced messenger RNA (mRNA) expres-
sion is signiﬁcantly associated with poor patient sur-
vival.8,9 Moreover, Merritt et al. demonstrated that
levels of Dicer and Drosha are prognostic factors in
patients with ovarian cancer.10
In CRC, it has been demonstrated that a high expres-
sion (both at mRNA and protein level) of Dicer is signif-icantly related to poor survival, independent of gender,
age, tumour site, stage and diﬀerentiation.11,12
Intriguingly, several studies have shown that Dicer
and Drosha play a crucial role during the angiogenic
process in vitro and that Dicer is also involved in the
angiogenesis regulation in in vivo models.13 In fact,
genetic silencing of Dicer in a mouse model was found
to impair normal morphogenesis and organ develop-
ment due to a de-regulation of angiogenesis-related
genes.14
Nowadays Bevacizumab, a humanised recombinant
monoclonal antibody that inhibits vascular endothelial
growth factor A (VEGF-A), is part of the standard
ﬁrst-line treatment for metastatic CRC.15,16
Based on these data, our aim was to investigate the
expression of Dicer and Drosha and their role as prog-
nostic and predictive factors of response to Bev-
acizumab-based treatment in advanced CRC patients.
2. Patients and methods
2.1. Exploratory review of microarray data
We decided to query the cancer microarray database
Oncominee (Compendia Bioscience, Ann Arbor, MI,
USA, version 4.4) for the mRNA expression of Dicer
and Drosha, in order to have a large overview of the
expression of our genes of interest across existing data-
sets. We decided to set a threshold P-value of 0.05 and
fold change of 2 in order to include comparisons in
our exploratory analysis. A gene/probe had to appear
in the top 10% of the ranking to include the series in
the analysis. The co-expression analysis in the signiﬁcant
series was also considered.
2.2. Study population
In our study we retrospectively included three diﬀer-
ent groups of patients, seen at the Campus Bio-Medico
University of Rome (Departments of Medical Oncology
and General Surgery) and aﬀected by: (1) advanced
CRC treated with Bevacizumab-containing regimens,
(2) advanced CRC treated with not Bevacizumab-con-
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rectal surgery (control group). For all patients, forma-
lin-ﬁxed paraﬃn-embedded (FFPE) surgical specimens,
collected prior to start of any therapy and clinico-path-
ological data were available. Clinical response to ther-
apy was based on RECIST criteria. Exclusion criteria
were preoperative (neo-adjuvant) chemotherapy and/or
radiotherapy.
Moreover, we collected peritumoural samples from a
subgroup of patients who received Bevacizumab-con-
taining regimens.
Samples were collected from January 2009 to Decem-
ber 2010; the median follow-up of patients was
21 months. Primary endpoints were to evaluate a poten-
tial association between the modulation of Dicer and
Drosha expression levels and progression free survival
(PFS), response rate and overall survival (OS). The
other prognostic variables tested were: tumour grading,
liver involvement, number of involved organs, perfor-
mance status (PS), albumin, alkaline phosphatase,
gamma-GT, LDH and basal CEA levels. REMARK cri-
teria were satisﬁed.2.3. RNA extraction and gene expression analysis
FFPE sections were treated with xylene and ethanol
to remove paraﬃn; the tissue was dried and resuspended
in Digestion Buﬀer and Proteinase K (Qiagen, UK) to
allow sample lysis. The tissue was digested overnight
at 56 C and total RNA was extracted using the TRizol
reagent (Invitrogen, CA, USA) according to the manu-
facturer’s instructions. RNA was treated with DNase
Buﬀer and DNase (DNAse Turbo, Applied Biosystems,
CA, USA) to avoid genomic DNA contamination. The
concentration and purity of the isolated RNA (A260/
A280 ratio between 1.8 and 2.0 were accepted) were
measured using a NanoDrop ND-1000 Spectrophotom-
eter (Thermo Fisher Scientiﬁc, DE, USA).
cDNA was produced using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, CA,
USA) according to the manufacturer’s recommenda-
tions and cDNA synthesis was performed with the fol-
lowing programme: 25 C 10 min (min), 37 C 120 min
and 85 C 5 min.
mRNA levels were measured by quantitative real-
time polymerase chain reaction (qRT-PCR) using
TaqMane Gene Expression Assays in 7900HT Real-
Time PCR System (Applied Biosystems, CA, USA). In
all samples, Dicer (Hs00229023_m1) and Drosha
(Hs00203008_m1) expression levels were normalised to
the endogenous housekeeping gene GUSb
(Hs99999908_m1) using the DCT calculation. Three
technical replicates of all samples were performed and
analysed; ddH2O, as non-template control, was ana-
lysed for every reaction mix. PCR cycling included the
following steps: 1 cycle at 95 C for 10 min, 45 times at95 C 15 s and 60 C for 1 min. Dicer and Drosha rela-
tive expression in all tumour samples was subsequently
normalised to their median expression values in normal
mucosa using the DDCT calculation.17
To conﬁrm Dicer protein expression, immunohisto-
chemistry with anti-DICER1 antibody (HPA000694,
Sigma) was performed.2.4. Statistical analysis
For all statistical analyses the programme SPSS 17.0
(SPSS, Chicago) was used. The ﬁnal mRNA levels were
converted to ratios of decreased expression (61) or
increased expression (>1) relative to levels of Dicer
and Drosha mRNA in healthy mucosa.10 Student’s t-
test was used to examine the diﬀerences in Dicer and
Drosha mRNA levels between samples. Student’s t-test
or one-way ANOVA method was applied to analyse
the relationships with clinical outcome. Kaplan–Meier
method was used to depict survival curves and Cox’s
Proportional Hazard Model estimated the correlation
between mRNA expression value and patients survival
in univariate and multivariate analyses. P-values <.05
were considered statistically signiﬁcant.3. Results
3.1. DNA microarray data
By querying for Dicer (probe 213229_at, Human
Genome U133 Plus 2.0 Array) we obtained a total of
29 eligible comparison analyses (cancer versus normal)
across several types of cancers whose three analyses
were available for CRC, all derived from the series pub-
lished by Kaiser et al. Fig. S1 shows Dicer mRNA
expression across the samples in the Kaiser microarray
dataset. As shown in Table S1, a statistically signiﬁcant
diﬀerence exists in Dicer expression between healthy
mucosa and rectal/rectosigmoid adenocarcinomas
(including mucinous histotype). In fact, rectal adenocar-
cinomas overexpress Dicer with a fold change >2 versus
normal mucosa. The expression of Dicer in colon adeno-
carcinomas is also signiﬁcantly up-regulated compared
to normal colon mucosa, but at lesser extent (fold
change 1.7–2.0) (Table S1).18 By querying for Drosha
we obtained only seven eligible comparison analyses
(cancer versus normal) across several types of cancers,
of which none was available for CRC.3.2. Experimental phase: patient population
We retrospectively selected 116 consecutive patients
treated with Bevacizumab-containing regimens for
advanced CRC, 50 consecutive patients aﬀected by
advanced CRC not treated with Bevacizumab-contain-
ing regimens and 20 consecutive patients who underwent
Table 1
Main clinical characteristics of Bevacizumab treated/untreated
patients with advanced CRC.
Patients characteristics Beva Pts # (%) Non Beva Pts #
(%)
Total number 116 (100) 50 (100)
M/F 62/54 (53%/47%) 39/21 (78%/22%)
Age (ys)
Median 64 63
Range 23–81 34–79
Performance status (Karnofsky)
Median 80 80
Range 50–100 40–100
Primary tumour site
Colon 78 (67%) 32 (64%)
Rectum 38 (33%) 18 (36%)
No. of metastatic sites
1 49 (42%) 21 (42%)
2 43 (37%) 18 (36%)
P3 24 (21%) 11 (22%)
Prior adjuvant therapy
None 29 (26%) 12 (24%)
FU/LVa 40(34%) 23 (46%)
FOLFOX regimen 47 (40%) 15 (30%)
First line regimen
Bevacizumab + FOLFOX 69 (59%)
Bevacizumab + FOLFIRI 47 (41%)
FOLFOX – 28 (56%)
FOLFIRI – 22 (44%)
Cumulative median PFS 11.5 8.8
(ITT population), mo (95% CI 10.88–
12.11)
(95% CI 5.97–9.9)
Cumulative median OS,
mo
28 18.9
(95% CI 24.54–
31.45)
(95% CI 12.19–
29.30)
Abbreviations: CI, conﬁdence interval; F, female; FU, ﬂuorouracil;
ITT, intention to treat; LV, leucovorin; M, male; mo, months; OS,
overall survival; PFS, progression free survival; ys, years.
a Symbols: according to Mayo Clinic or De Gramont schedules.
Fig. 1. Dicer expression in human colon cancer. Colon cancer with high lev
cytoplasm for anti-Dicer1 antibody (A). Diﬀerently, colon cancer with
immunoreaction (B). Original magniﬁcation 200.
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116 patients who received Bevacizumab-based regimens
underwent radiological restaging. Moreover we collected
peritumoural samples from 53 of the 116 consecutive
patients who received Bevacizumab-containing regi-
mens. Table 1 summarises the clinico-pathological
features of the 116 and 50 patients treated/untreated with
Bevacizumab-containing regimens respectively.
3.3. Dicer and Drosha mRNA expression in normal
mucosa, peritumoural margins and primary tumours in
Bevacizumab-treated patients
The mRNA levels of Drosha in peritumoural margins
(n = 53, median = 19.19, CI 95% 16.27–21.11) and pri-
mary tumour (n = 116, median = 24.55, CI 95% 20.40–
40.59) were signiﬁcantly increased (P = .04 and <.001,
respectively) compared to the levels in normal mucosa
samples resected from patients with diverticulosis (med-
ian = 12.45, CI 95% 4.32–16.11). Conversely, Dicer
expression levels did not show any signiﬁcant diﬀerence
between normal mucosa (median = 1,42) and peritumo-
ural (median = 1,25; P = .09) or tumoural samples
(median = 1,28; P = .080).
Dicer protein expression was conﬁrmed by immuno-
histochemistry (Fig. 1).
3.4. Dicer and Drosha association with clinical outcome in
Bevacizumab-treated patients
A statistically signiﬁcant correlation was found
between Dicer expression levels and PFS (P < .0001,
CI 95% 10,8–12.1) and OS (P = .009, CI 95% 24.5–
31.4) in Bevacizumab-treated patients with advanced
CRC (Table 2). These results suggested a strong associ-
ation between low Dicer levels and favourable outcome,
in terms of PFS and OS. On the other hand, Droshael of mRNA Dicer expression shows signiﬁcant staining in tumour cell
low level of mRNA Dicer expression was negative for anti-Dicer1
Table 2
Dicer and Drosha expression levels and clinical outcome.
Dicer mRNA level Median PFS (95% CI) mo P value
Low 13.2 (11.77–14.62) <.0001
High 9.7 (9.03–10.46)
Median OS (95% CI) mo
Low 31.0 (25.52–36.47) =.009
High 24.0 (19.89–28.10)
Drosha mRNA level Median PFS (95% CI) mo
Low 12.8 (11,81–13.78) =.254
High 10.0 (8.93–11.06)
Median OS (95% CI) mo
Low 28.0 (24.71–31.28) =.262
High 25.0 (21.63–28.36)
Abbreviations: CI, conﬁdence interval; mo, months; PFS, progression-
free survival; OS, overall survival.
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cant correlation with clinical outcome (PFS: P = .254,
CI 95% 10.8–12.1; OS: P = .262, CI 95% 24.5–31.4)
(Fig. 2; Table 2). Additionally, the response to Bev-
acizumab-based treatment according to RECIST crite-
ria was evaluated on the basis of Dicer/Drosha levels.
Patients with low Dicer expression levels showed a bet-
ter response to Bevacizumab-based therapy (1.7% com-
plete responses (CR) and 53.4% partial responses (PR);
P = .0067) compared to patients with high Dicer mRNA
levels (0% CR and 32.7% PR), as shown in Table 3. The
same results were not observed for Drosha.
In the multivariate analysis that included PS, number
of organs involved, carcinoembryonic antigen and low
dicer, the relationship between low Dicer and survival
remained signiﬁcant (PFS: P = .006, RR = 0.48, 95%
CI 0.33–0.81; OS: P = .008, RR = 0.55, 95% CI 0.40–
0.86 for) as shown in Table 4. Other prognostic variables
tested such as tumour grading, liver involvement, albu-
min, alkaline phosphatase, gamma-GT and LDH have
not shown statistical signiﬁcance.
3.5. Dicer and Drosha association with clinical outcome in
patients not treated with Bevacizumab-based therapy
In order to assess the potential role of Dicer and Dro-
sha in predicting eﬃcacy of Bevacizumab-based treat-
ments, we analysed Dicer and Drosha expression levels
in a control group of patients aﬀected by advanced
CRCnot treatedwith Bevacizumab-containing regimens.
In this group of patients, their expression levels did not
show any statistically signiﬁcant correlation with survival
(Table 5) suggesting a potential predictive role of Dicer in
response to the anti-angiogenetic based treatment.
4. Discussion
Several preclinical evidences elucidated the role of the
two key enzymes for miRNA biogenesis Dicer andDrosha in angiogenesis and endothelial function. In a
model of human endothelial cells (ECs) the Dicer or
Drosha silencing leads to a slight decrease in angiogen-
esis, evaluated by endothelial tube formation in matri-
gel.13 In a mouse Dicer knock-down model, it has
been demonstrated that endothelial miRNAs are
required for postnatal angiogenesis in response to angio-
genic stimuli. Indeed this model showed a decreased post-
natal angiogenesis after Dicer knock-down in response to
diﬀerent stimuli such as exogenous VEGF, tumours,
ischaemia and wound healing.13,19–21 Interestingly,
Kuehbacher et al. found that migration of ECs was signif-
icantly decreased in Dicer siRNA–transfected cells,
whereas Drosha siRNA had no eﬀect.13 Silencing of Dicer
but not of Drosha seems to reduce angiogenesis in vivo.
Starting from these preclinical data is reasonable to
think that diﬀerential expressions of Dicer and to a les-
ser extent Drosha in cancer patients could inﬂuence the
outcome and the eﬃcacy of treatments based on angio-
genesis inhibitors. To investigate these hypotheses we
evaluated whether Dicer and Drosha showed diﬀerent
mRNA expression levels in 116 CRC samples and 20
normal mucosa tissues from patients with diverticulosis.
Moreover, we analysed peritumoural sections from 53 of
the 116 tumour samples in order to investigate if they
had a similar expression proﬁle compared to normal
mucosa samples from patients resected for diverticular
disease. We found a statistically signiﬁcant increase in
the median mRNA levels of Drosha in tumour sections
compared to peritumoural samples and healthy mucosa.
It is presumable that the peritumoural tissue, which is
assumed to be not impaired during cancer formation
and apparently normal at morphological level, could
show abnormal gene regulation in comparison to nor-
mal mucosa from non-cancer patients supporting its
involvement both in early cancer formation and in the
progression. However, these data need further investiga-
tion. Conversely, we did not found any signiﬁcant diﬀer-
ence in Dicer expression levels among our three groups
of samples.
Stratmann et al. found that Dicer expression was
increased in primary tumours in comparison to that in
normal mucosa from rectal cancer patients but this
was not evident in colon cancer patients; moreover its
expression was higher in rectal cancer than in colon
cancer.12
Analysing the Bevacizumab treated patient group we
interestingly observed that low Dicer expression was
associated with a favourable outcome in terms of PFS
and OS, independently of other clinical parameters.
Indeed patients with low Dicer expression levels pre-
sented a better response to Bevacizumab-based therapies
compared to patients with high Dicer levels. These data
are in accordance with previous studies that showed a
direct involvement of Dicer in the development and clin-
ical outcome of malignancies such as ovarian, prostate
Fig. 2. Kaplan–Meier curves of PFS (panel A) and OS (panel B) show that low Dicer expression levels correlate with longer PFS (P < .0001) and
OS (P = .009) in patients with mCRC treated with Bevacizumab containing regimens; Kaplan–Meier curves of PFS (panel C) and OS (panel D)
show that low/high Drosha expression is not signiﬁcantly associated to diﬀerence in terms of OS and PFS in patients with mCRC treated with
Bevacizumab containing regimens.
Table 3
DICER and DROSHA expression and clinical response.a
mRNA level # CR (%) # PR (%) # SD (%) # PD (%)
Low Dicer 1 (1.7%) 31 (53.4%) 15 (25.8%) 11 (18.9%)
High Dicer 0 (0%) 19 (32.7%) 20 (34.4%) 19 (32.7%)
Low Drosha 1 (1.7%) 27 (46.5%) 17 (29.3%) 13 (22.4%)
High Drosha 0 (0%) 23 (39.6%) 18 (31%) 17 (29.3%)
Abbreviations: CR, complete response; PD, progressive disease PR, partial response; SD, stable disease.
a According to RECIST (1.0) criteria.
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expression did not signiﬁcantly correlate with prognosis.However, analysing the Dicer expression levels in the
50 patients untreated with Bevacizumab-based regimens
Table 4
Multivariate analysis for PFS and OS.
Factors Univariate Multivariate
RR 95% CI P RR 95% CI P
PFS
PS (70–80 versus 81–100) 1.31 1.06–1.76 .034 1.15 0.67–1.35 .322
N organs involved (1 versus more) 0.82 0.63–0.96 .021 0.95 0.61–0.98 .047
Low Dicer 0.48 0.27–0.69 <.0001 0.67 0.33–0.81 .006
OS
PS (70–80 versus 81–100) 1.91 1.22–2.51 .004 1.45 1.16–2.23 .011
N organs involved (1 versus more) 0.68 0.51–0.91 .008 0.79 0.60–0.95 .034
Low Dicer 0.55 0.32–0.87 0.003 0.71 0.40–0.86 .008
CEAa 1.31 1.05–1.97 .035 1.09 0.88–1.41 .318
Abbreviations: CEA, carcinoembryonic antigen; CI, conﬁdence interval; N, number; PFS, progression-free survival; PS, performance status; RR,
relative risk; OS, overall survival.
a Symbols: continuous variable for every 50-point CEA increase.
Table 5
Dicer and Drosha expression levels and patient outcome in the control
group (FOLFOX IV).
Dicer mRNA level Median PFS (95% CI) mo P value
Low 9.8 (5.06–14.1) .639
High 8.7 (4.87–10.84)
Median OS (95% CI) mo
Low 24.0 (18.20–31.88) .416
High 21.4 (16.99–27.01)
Drosha mRNA level Median PFS (95% CI) mo P value
Low 9.4 (5.98–13.02) .860
High 8.6 (5.41–11.97)
Median OS (95% CI) mo
Low 23.9 (17.22–27.17) .761
High 22.8 (16.84–26.10)
Abbreviations: CI, conﬁdence interval; mo, months; PFS, progression-
free survival; OS, overall survival.
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patient survival.
These data do not seem to support a possible Dicer
prognostic role in mCRC, as previously published in lit-
erature, suggesting, hence, a potential role of Dicer as a
biological parameter that could predict the eﬃcacy of an
anti-angiogenetic therapy.11
As mentioned above, data from literature show that
Dicer could be directly involved in the regulation of
VEGF-dependent angiogenetic processes. Preclinical
results indicate that transient reduction of the miR-
NA-regulating enzyme Dicer impairs angiogenesis
in vitro and in vivo, whereas Drosha siRNA induced a
minor antiangiogenic eﬀect in vitro and is not eﬀective
in vivo.13 Speciﬁcally, Dicer down-regulation demon-
strated to induce an increase in expression level of sev-
eral key genes involved in regulation of endothelial
biology and angiogenesis, such as TEK/Tie2, KDR/
VEGFR2, Tie-1, eNOS and IL-8.21 Moreover, Dicer
silencing leads to strong up-regulation of the potent
angiogenesis inhibitor thrombospondin-1 (Tsp-1), iden-
tiﬁed also by in silico analysis.13 Tsp-1 is a predicted tar-get of the Let-7 family and the miR-17-92 cluster and
Dicer and Drosha siRNA reduced lef-7f and miRNA-
27b expression.13 Interestingly, inhibitors of Let-7f,
miRNA-17-92 and miRNA-27b clusters reduce EC
sprouting and matrigel tube formation in vitro, indicat-
ing that these miRNAs promote angiogenesis by target-
ing antiangiogenic genes.13,21 Notably, by looking at the
most co-expressed genes with Dicer in Kaiser micro-
array dataset, our analysis identiﬁed among the top 15
ranked genes ATRX and NKTR (correlation 0.59 for
both), both targeted by miRNA-27b.19
On the basis of these evidences, our clinical study
provides an initial support to the hypothesis of an
increased eﬃcacy of Bevacizumab-based treatments in
patients with low levels of Dicer and consequent impair-
ment of angiogenesis pathways. This correlation is not
observed for Drosha, conﬁrming both clinical and pre-
clinical results.
Further studies are also warranted to deeper investi-
gate the relationship between potential Dicer-dependent
targets (e.g. let-7 family and mir-27b) and angiogenesis
modulation in CRC patients. Moreover in order to con-
ﬁrm these very preliminary results, we consider manda-
tory their validation into prospective and larger
translational studies. If conﬁrmed, these data would fur-
ther support the use of Dicer expression level as predic-
tive marker of response to Bevacizumab-based therapy
in advanced CRC, helping the clinicians to choose the
optimal personalised therapy for advanced CRC
patients.
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